HC Wainwright Lowers Earnings Estimates for Ekso Bionics

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Investment analysts at HC Wainwright lowered their Q2 2025 earnings per share (EPS) estimates for Ekso Bionics in a note issued to investors on Tuesday, May 6th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.08) per share for the quarter, down from their previous estimate of ($0.05). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Ekso Bionics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Ekso Bionics’ Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.34) EPS, FY2026 earnings at ($0.22) EPS, FY2027 earnings at ($0.11) EPS, FY2028 earnings at ($0.01) EPS and FY2029 earnings at $0.08 EPS.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The firm had revenue of $3.38 million during the quarter, compared to the consensus estimate of $4.62 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%.

A number of other equities analysts have also weighed in on the stock. StockNews.com initiated coverage on shares of Ekso Bionics in a report on Tuesday. They issued a “hold” rating for the company. Lake Street Capital decreased their price target on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th.

Ekso Bionics Trading Up 1.6 %

Shares of NASDAQ EKSO opened at $0.42 on Thursday. The firm’s 50 day moving average price is $0.42 and its 200-day moving average price is $0.59. Ekso Bionics has a 52-week low of $0.34 and a 52-week high of $1.53. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The company has a market cap of $12.19 million, a PE ratio of -0.65 and a beta of 1.09.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.